Our partners
One of the things that makes AVEO stand out in our industry is the ability to collaborate with others who share our vision. By seeking out strong pharmaceutical and biotechnology partners, we are able to work together efficiently to bring cancer treatments to those who need them.
Who we work with
AVEO has the license to develop, manufacture, and commercialize tivozanib in all areas of the world except for Asia and the Middle East. The agreement also allows for clinical data information sharing.
AVEO Licensing agreement grants Recordati the European rights to tivozanib. Recordati may use study data in return for research and development funding to AVEO.
AVEO entered into an exclusive development and option agreement to develop HiberCell’s first-in-human PERK inhibitor, HC-5404, alone and in combination with FOTIVDA® (tivozanib). AVEO is responsible for conducting clinical development and we have an exclusive option to obtain a license for the development, manufacturing, and commercialization of HC-5404 in all therapeutic indications worldwide.
Alliance for Clinical Trials in Oncology Foundation
Research grant agreement to evaluate safety and efficacy of tivozanib in combination with pembrolizumab in a Phase 3 clinical trial for adjuvant treatment of renal cell carcinoma.
MD Anderson University of Texas
Investigator-initiated trial research agreement to evaluate safety and efficacy of tivozanib in combination with nivolumab in advanced non-clear cell renal cell carcinoma in a Phase 2 study.
National Cancer Institute’s Surgical Oncology Program
Cooperative research and development agreement to evaluate safety and efficacy of tivozanib in cholangiocarcinoma in a Phase 1-2 clinical trial.
University of Florida
Investigator-sponsored trial agreement to evaluate safety and efficacy of tivozanib in combination with atezolizumab in immunologically cold tumors in a Phase 1b/2 clinical trial.
Blood Cancer United
Clinical Trial Collaboration Agreement to evaluate the safety and preliminary efficacy of ficlatuzumab in combination with azacitidine and venetoclax in untreated acute myeloid leukemia in a Phase 1b/2 clinical trial sub-study under the Beat AML® Master Clinical Trial.